Stone Realty Group Analysis Finds Charlotte Housing Market Is Splitting Into Distinct Buyer and Seller Micro-Markets

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

Kulani Kinis Makes Miami Swim Week Debut with "Endless" Runway Experience and SOJOS Eyewear Collaboration

CPKC to maintain rail operations across Canada during IBEW strike

CPKC to maintain rail operations across Canada during IBEW strike

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in...

Liuuve AI Dropshipping combines AI live streaming with a global supply chain to make selling smarter and starting a business simpler

James Altucher Spent Months Researching the Technology Behind the SpaceX IPO. He Put Everything Into One Presentation and Released It for...

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in...

Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting...

Media Advisory - Secretary of State van Koeverden to attend Canada's Men's National Team friendly soccer match in Edmonton

Why AI Visibility Operating Systems Are Replacing Fragmented Marketing Strategies

Media Advisory - Secretary of State van Koeverden to announce funding for Indigenous-led sport initiatives across Canada

Village Voyage: Where China's rural soul meets the world

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where...

Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of...

AI Is Reshaping Crypto Faster Than Anyone Expected as AIX Alpha’s New System Signals the Shift

How McKinney Plans for 400,000 Residents and a 24/7 Digital Ecosystem

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial...

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with...